Brilinta: Medgend

Brilinta FDA Approved Drugs

BRILINTA [Ticagrelor^{C₂₃H₂₈F₂N₆O₄S}]

60mg (oral tablet)

90mg (oral tablet)

Astrazeneca Pharms^{Sep 3, 2015}

Method of inhibiting platelet aggregation.
Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction.
Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
Reduction of the rate of thrombotic events in patients with acute coronary syndrome.
Treatment of an arterial thrombotic complication in a patient with coronary artery, cerebrovascular or peripheral vascular disease.
Treatment of arterial thrombotic complications selected from the group consisting of unstable angina, thrombotic or embolic stroke, transient ischaemic attacks, peripheral vascular disease and myocardial infarction.
Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
Treatment of myocardial infarction in patients with acute coronary syndrome or a history of myocardial infarction.
Treatment of myocardial infarction.
Treatment of post-myocardial infarction.
Treatment of stable and unstable angina.
Treatment of stroke in patients with acute coronary syndrome or a history of myocardial infarction.
Treatment of stroke.
Treatment of thrombotic stroke.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.